Chinese OTC Drugmaker Warned for Process Control Failures

Drug Industry Daily
A A
The FDA issued a warning letter to Longood Medicine, a Beijing-based drugmaker, for process control violations and for using an unapproved drug in the formulation of one of its products.

To View This Article:

Login

Subscribe To Drug Industry Daily